Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

COVID-19 vaccine-elicited immune responses in myeloma patients

Researchers collaborated to address these evidence gaps by initiating a web-based prospective study of adults diagnosed with multiple myeloma to determine the immune response to the first and second dose of the COVID-19 vaccine.

27 Oct 2021

Study of SARS-CoV-2 antibody seroprevalence among domestic cats

Researchers from the University of Veterinary Medicine Hannover have been investigating the spread of the disease in domestic cats in Europe.

27 Oct 2021

bit.bio expands Board of Directors with appointment of entrepreneurs and Nobel Laureate

Today bit.bio welcomed three new members to its Board of Directors, who bring their respective experience of turning world-class science into new industries.

From bit.bio 27 Oct 2021

New study explains why Delta is so easily transmitted and infects people quickly

The Delta variant of SARS-CoV-2 has swept the globe, becoming the dominant variant within just a few months. A new study from Boston Children's Hospital, published today in Science, explains why Delta is so easily spread and infects people so quickly, and suggests a more targeted strategy for developing future COVID-19 vaccines and treatments.

27 Oct 2021

Moderna’s COVID-19 vaccine provides durable protection against SARS-CoV-2 delta in macaques

Researchers in the United States have conducted a study showing that Moderna’s coronavirus disease 2019 (COVID-19) vaccine provided durable protection against the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus macaques.

26 Oct 2021

Hyperimmune antibody produced in horses may be an efficient approach to combat covid-19

A study conducted by a consortium of Brazilian researchers has demonstrated that a hyperimmune serum consisting of purified antibody fragments produced in horses may be an efficient approach to combat covid-19.

26 Oct 2021

Model suggests longer protection from SARS-CoV-2 neutralizing antibody response

A new study discusses the durability of the immune response following natural infection or vaccination.

26 Oct 2021

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Israeli researchers evaluate the antibody response in ICPs to assess antibody-mediated immunity following vaccination with the Pfizer-BioNTech vaccine.

26 Oct 2021

Study finds SARS-CoV-2 infection is proportional to cell surface ACE2 levels

Researchers from Oregon State University have developed a system to assess the ability of SARS-CoV-2 to bind to ACE2 orthologs.

26 Oct 2021

MIP Diagnostics to support the development of challenging affinity reagents with new Molecular Imprinting Epitope Discovery

MIP Diagnostics has today announced the launch of its novel Molecular Imprinting Epitope Discovery Service.

26 Oct 2021

Study identifies how cancer cells transform macrophages into supporters of their growth

A Ludwig Cancer Research study has identified a means by which cancer cells engineer the conversion of immune cells known as macrophages from destroyers of tumors to supporters of their growth and survival.

26 Oct 2021

Sexually dimorphic placental antibody transfer during SARS-CoV-2 infection

In a paper recently published in the journal Science Translational Medicine by Bordt et al. (October 19th, 2021), maternal SARS-CoV-2 infections are studied with particular regard to maternal-fetal antibody transfer and virus-induced placental interferon responses, finding a sexually dimorphic response that results in lesser antibody transfer to the male fetus.

26 Oct 2021

Immune response to mRNA COVID vaccines delayed in pregnant women

Researchers in the United States have conducted comprehensive profiling of humoral immune responses in pregnant, lactating, and non-pregnant women following coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccination to probe differences in vaccine-induced immunity.

25 Oct 2021

Can targeting autophagy become a new approach to COVID-19 treatment?

In a recent review, the author discusses autophagy as a contributing mechanism of selected drugs that are currently being evaluated to treat COVID‐19.

25 Oct 2021

Molecular features of SARS-CoV-2 variant receptor binding

Researchers have been investigating the changes in receptor binding in these variants that increase the danger they pose.

25 Oct 2021

How pregnancy influences SARS-CoV-2 immune response

A focus article published in Science Translational Medicine highlighted two recently published studies that investigated the response of pregnant women to natural infections and COVID-19 vaccines.

25 Oct 2021

Study suggests seropositive individuals produce anti-SARS-CoV-2 antibodies with improved potency and breadth

Researchers isolated single cells among individuals with and without prior infection with the SARS-CoV-2 vaccinated with BNT162b2 mRNA vaccine and compared the nature of the neutralizing antibody response against the original Wuhan virus and the subsequent variants.

25 Oct 2021

EKF Diagnostics to exhibit new STAT-Site WB β-ketone and glucose handheld analyzer at Medica 2021

EKF Diagnostics, the global in vitro diagnostics company, announces that it will be exhibiting live & in person at Medica 2021 (Hall 3 Stand B71) for the first time in mainland Europe in two years.

From EKF Diagnostics 25 Oct 2021

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.

25 Oct 2021

A comparison between Pfizer/BioNTech's and Sinopharm's SARS-CoV-2 vaccines

Researchers compare antibody titers elicited the Pfizer‐BioNTech mRNA and the classic inactivated virus Sinopharm vaccines.

24 Oct 2021

Antibody News and Research

Further Reading

COVID-19 vaccine-elicited immune responses in myeloma patients

Study of SARS-CoV-2 antibody seroprevalence among domestic cats

bit.bio expands Board of Directors with appointment of entrepreneurs and Nobel Laureate

New study explains why Delta is so easily transmitted and infects people quickly

Moderna’s COVID-19 vaccine provides durable protection against SARS-CoV-2 delta in macaques

Hyperimmune antibody produced in horses may be an efficient approach to combat covid-19

Model suggests longer protection from SARS-CoV-2 neutralizing antibody response

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Study finds SARS-CoV-2 infection is proportional to cell surface ACE2 levels

MIP Diagnostics to support the development of challenging affinity reagents with new Molecular Imprinting Epitope Discovery

Study identifies how cancer cells transform macrophages into supporters of their growth

Sexually dimorphic placental antibody transfer during SARS-CoV-2 infection

Immune response to mRNA COVID vaccines delayed in pregnant women

Can targeting autophagy become a new approach to COVID-19 treatment?

Molecular features of SARS-CoV-2 variant receptor binding

How pregnancy influences SARS-CoV-2 immune response

Study suggests seropositive individuals produce anti-SARS-CoV-2 antibodies with improved potency and breadth

EKF Diagnostics to exhibit new STAT-Site WB β-ketone and glucose handheld analyzer at Medica 2021

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

A comparison between Pfizer/BioNTech's and Sinopharm's SARS-CoV-2 vaccines

Event guide: Targeted Therapies Partnering & Licensing Summit Asia eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo